InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
0
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-19.4%
Across 6 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by ROSENZWEIG RICHARD C, Vice-Président Senior et Conseiller Juridique Général. Insider active across 2 companies, notably Angiodynamics INC. Cumulatively, 19 filings have been recorded. History available since 21 July 2021. The latest transaction was disclosed on 11 April 2025 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Declarations19 total
628.48 shares0Common StockSEC:0001127602-25-012079:0
33,771 shares0Common StockSEC:0001127602-25-008393:0
383.448 shares0Common StockSEC:0001127602-25-001225:0
266.906 shares0Common StockSEC:0001127602-24-025513:0
287.985 shares0Common StockSEC:0001127602-24-020399:0
215.105 shares0Common StockSEC:0001127602-24-012907:0
11,644 shares0Common StockSEC:0001127602-24-008810:0
1,356 shares@ US$33.27100.0% of flowCommon StockSEC:0001127602-24-008232:0
193.809 shares0Common StockSEC:0001127602-24-001317:0
201.097 shares0Common StockSEC:0001127602-23-025917:0
171.053 shares0Common StockSEC:0001127602-23-020837:0
173.656 shares0Common StockSEC:0001127602-23-013150:0
10,003 shares0Common StockSEC:0001127602-23-009260:0
1,137 shares@ US$13.3623.6% of flowCommon StockSEC:0001567619-23-002003:0
3,963 shares0Common StockSEC:0001567619-22-014369:0
1,194 shares@ US$21.310.0051% mcap50.0% of flowCommon StockSEC:0001567619-22-002444:0
1,194 shares@ US$21.3138.2% of flowCommon StockSEC:0001567619-22-002444
3,098 shares0Common StockSEC:0001567619-21-013914:0
3,098 shares0Common StockSEC:0001567619-21-013914
19 of 19 declarations
About ROSENZWEIG RICHARD C
Richard C. Rosenzweig is the Senior Vice President and General Counsel of AngioDynamics Inc. He is responsible for the company's legal affairs, including regulatory compliance and risk management. His legal expertise is essential in protecting AngioDynamics's interests.
